<DOC>
	<DOCNO>NCT00343759</DOCNO>
	<brief_summary>The purpose study see kind breast tumor respond lapatinib . Lapatinib experimental medicine may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Presurgical Therapy With Lapatinib Explore Molecular Determinants Response EGFR/erbB2 Targeted Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histologically cytologicallyconfirmed either core fine needle biopsy primary invasive carcinoma breast ; AJCC T2T3 disease ( &gt; 2.0 cm without chest wall skin invasion ) least one image modality ( either mammogram , ultrasound , MRI ) entry criterion base radiologic stag final pathologic staging ; ECOG performance status 01 ( Karnofsky ≥ 70 % Any lymph node status , hormone receptor status , level erbB2 expression No prior chemotherapy , hormonal therapy radiation therapy affect breast current previous malignancy ; Cardiac ejection fraction &gt; 50 % within institutional range normal ; Patients must normal organ marrow function define : Leukocyte count &gt; 3000/uL ; Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 , platelet &gt; 100,000/mm3 , hemoglobin ≥ 8 gm/dl ; Serum creatinine ≤ 1.5 time ULN , 24hour creatinine clearance ≥ 75 cc/min ; Serum bilirubin ≤ 1.5 time ULN ; SGOT ≤ 2.5 time ULN ; alkaline phosphatase ≤ 2.5 ULN time ULN . The effect lapatinib develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign write informed consent document . AJCC T1 , T4 , stage 4 disease ; Patients may undergo incisional excisional biopsy tumor ; Patients may receive investigational agent ; Absolute contraindication MRI imaging ( cardiac pacemaker nonremovable metallic foreign object body ) ; On chronic therapy know inducer inhibitor CYP3A4 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant lactate woman exclude study lapatinib tyrosine kinase inhibitor potential teratogenic abortifacient effect .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Biologic response modifier</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>Treatment-naive , operable</keyword>
</DOC>